Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Generalized Myasthenia Gravis (gMG)

NCT06987539 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06987539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06987539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Generalized Myasthenia Gravis (gMG)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Recruiting
Start date
July 21, 2026
Completion date
March 13, 2030
Enrollment
15 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis